Skip to content
DraconiticResearch
Search Sources API
182,469 studies31 sourcesUpdated 37 min ago
Peer-reviewedCC BYCurrent oncology (Toronto, Ont.)

Association Between ABO Blood Group and Survival Outcomes in Advanced NSCLC Treated with Immune Checkpoint Inhibitors.

  • Hilal Karakaş1
  • Safa Can Efil1
  • Burak Bilgin1
  • Mehmet Ali Nahit Şendur1
  • Murat Bardakçı2
  • Perihan Perkin1
  • Yakup Ergun3
  1. 1Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara 06800, Türkiye.
  2. 2Department of Medical Oncology, Diyarbakır Gazi Yaşargil Training and Research Hospital, Diyarbakır 21070, Türkiye.
  3. 3Department of Medical Oncology, Bower Hospital, Diyarbakır 21070, Türkiye.
Read full textPDFDOICite

Abstract

Background

Reliable biomarkers that predict outcomes with immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) remain limited. ABO blood group antigens may influence tumor immunity and response to immunotherapy.Methods

We retrospectively analyzed 239 patients with advanced NSCLC treated with ICI-based therapy between 2019 and 2024. Patients were classified according to ABO blood group, and overall survival (OS), progression-free survival (PFS), and treatment response were evaluated.Results

Patients with blood group O had significantly longer OS (18.6 vs. 11.0 months; p < 0.001) and PFS (9.4 vs. 4.2 months; p = 0.001) than patients with non-O blood groups. In multivariable analyses, blood group O remained independently associated with improved OS and PFS.Conclusions

Blood group O may represent a simple and readily available host-related prognostic marker in patients with advanced NSCLC receiving ICI-based therapy. Prospective multicenter studies are required to validate these findings.

Related

  1. Long-term survival with immune checkpoint inhibitors combined with bevacizumab in advanced clear cell renal cell carcinoma : A case report
    Jing Zhang, Chun-Qiao Chen, Hui Huang +3
    MedicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  2. Association between antibiotic exposure and survival outcomes in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis
    Shuaihang Chen, Shanshan Chen, Yuanqiang Li +6
    PeerJPeer-reviewedCC BY 4.0Full textImmunologyOncologyCrossrefPMC
  3. Association of pre-existing cardiovascular disease with cardiovascular and clinical outcomes in patients receiving immune checkpoint inhibitors
    Lama Alfehaid, Ahmed S. Alanazi, Mansour Alomran +2
    Scientific ReportsPeer-reviewedCC BY-NC-ND 4.0Full textOncologyCrossref
  4. Sex difference in survival benefits of immune checkpoint inhibitors in advanced non-small cell lung cancer: A meta-analysis
    Tingting Liu, Dandan Song, Jun Chen +3
    PLOS OnePeer-reviewedCC BY 4.0Clinical trials & evidence synthesisOncologyPLOS
  5. Real-World Evidence of First- or Second-Line Immune Checkpoint Inhibitors Versus Chemotherapy in Advanced NSCLC: A Prospective Pragmatic Multicenter Korean Study
    Jinyong Kim, Sehhoon Park, Gyeong-Won Lee +16
    JTO clinical and research reportsPeer-reviewedCC BY-NC-NDFull textOncologyEurope PMC

Cite

BibTeXRIS
BibTeX
@article{karakas2026association,
  title = {{Association Between ABO Blood Group and Survival Outcomes in Advanced NSCLC Treated with Immune Checkpoint Inhibitors.}},
  author = {Hilal Karakaş and Safa Can Efil and Burak Bilgin and Mehmet Ali Nahit Şendur and Murat Bardakçı and Perihan Perkin and Yakup Ergun},
  journal = {Current oncology (Toronto, Ont.)},
  year = {2026},
  month = sep,
  doi = {10.3390/curroncol33100590},
  url = {https://europepmc.org/article/MED/42930157},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Association Between ABO Blood Group and Survival Outcomes in Advanced NSCLC Treated with Immune Checkpoint Inhibitors.
AU  - Hilal Karakaş
AU  - Safa Can Efil
AU  - Burak Bilgin
AU  - Mehmet Ali Nahit Şendur
AU  - Murat Bardakçı
AU  - Perihan Perkin
AU  - Yakup Ergun
PY  - 2026
DA  - 2026/09/30
JO  - Current oncology (Toronto, Ont.)
DO  - 10.3390/curroncol33100590
UR  - https://europepmc.org/article/MED/42930157
AB  - Background  Reliable biomarkers that predict outcomes with immune checkpoint inhibitors (ICIs) in non-small cell lung cancer (NSCLC) remain limited. ABO blood group antigens may influence tumor immunity and response to immunotherapy.Methods  We retrospectively analyzed 239 patients with advanced NSCLC treated with ICI-based therapy between 2019 and 2024. Patients were classified according to ABO blood group, and overall survival (OS), progression-free survival (PFS), and treatment response were evaluated.Results  Patients with blood group O had significantly longer OS (18.6 vs. 11.0 months; p < 0.001) and PFS (9.4 vs. 4.2 months; p = 0.001) than patients with non-O blood groups. In multivariable analyses, blood group O remained independently associated with improved OS and PFS.Conclusions  Blood group O may represent a simple and readily available host-related prognostic marker in patients with advanced NSCLC receiving ICI-based therapy. Prospective multicenter studies are required to validate these findings.
SN  - 1198-0052
SN  - 1718-7729
ER  -